PDF(Pubmed)
Abstract：
The incidence of chronic atrophic gastritis (CAG) is on the rise due to the growing pressure in modern social life, increasing bad living habits and emotional disorders (such as anxiety and depression), and the aging of the population. Of note, digestive system diseases are the dominant diseases in the field of traditional Chinese medicine (TCM). Therefore, this study evaluated the efficacy and safety of Piwei Peiyuan Prescription, a TCM prescription, in the treatment of CAG through a multicenter, double-blind, randomized, controlled design. This research was organized by the Second Affiliated Hospital of Anhui University of TCM and simultaneously performed in 6 centers. A total of 120 CAG patients were included and randomized into 2 groups: group A (treatment with Piwei Peiyuan granules plus Weifuchun Simulant) and Group B (treatment with Weifuchun Tablets plus Piwei Peiyuan Simulant). These 2 groups were compared in terms of gastroscopy scores, TCM syndrome scores, and serological indicators at baseline and within 12 weeks after treatment. According to endoscopic biopsy for pathological observation, atrophy (2.56 ± 1.08 vs 3.00 ± 1.00, P = .028) and intestinal epithelial hyperplasia (1.00 ± 1.43 vs 1.69 ± 1.80, P = .043) scores were lower in group A than in group B. For the more, group A had higher effective rates for inflammation, atrophy, and intestinal metaplasia (IM) in various regions of the stomach, especially for atrophy/IM of the gastric angle (64%, P = .034) and atrophy/IM of the lesser curvature of gastric antrum (63%, P = .042) than group B. According to TCM syndrome scores, Piwei Peiyuan Prescription improved the scores of gastric distension (2.30 ± 1.13 vs 2.80 ± 0.99, P = .022), preference for warmth and pressure (1.44 ± 1.06 vs 1.36 ± 1.10, P = .041), and poor appetite and indigestion (0.78 ± 0.66 vs 1.32 ± 0.72, P = .018). GAS, MTL, and PGE2 expression was significantly elevated after treatment with Piwei Peiyuan Prescription (P < .001). Piwei Peiyuan Prescription is effective for CAG treatment with high safety.
摘要：
慢性萎缩性胃炎(CAG)的发病率随着现代社会生活压力的增大而呈上升趋势,增加不良生活习惯和情绪障碍（如焦虑和抑郁），以及人口老龄化。值得注意的是，消化系统疾病是中医领域的优势疾病。因此,本研究评价了脾胃培元处方的有效性和安全性，中药处方，通过多中心治疗CAG，双盲,随机化，控制设计。本研究由安徽中医药大学第二附属医院组织，在6个中心同时进行。共纳入120例CAG患者，随机分为2组：A组（体味培元颗粒加胃复春模拟器治疗）和B组（体味培元片加胃复春模拟器治疗）。比较两组患者的胃镜评分,中医证候积分,基线和治疗后12周内的血清学指标。根据内镜活检进行病理观察,A组的萎缩（2.56±1.08vs3.00±1.00，P=.028）和肠上皮增生（1.00±1.43vs1.69±1.80，P=.043）评分低于B组。A组炎症有效率较高，萎缩,和胃各个区域的肠上皮化生（IM），特别是胃角萎缩/IM(64%，P=.034）和胃窦较小曲率的萎缩/IM（63%，P=0.042)比B组根据中医证候积分，脾胃培元方改善胃胀评分(2.30±1.13vs2.80±0.99,P=.022),对温暖和压力的偏好（1.44±1.06vs1.36±1.10，P=.041），食欲不振和消化不良（0.78±0.66vs1.32±0.72，P=0.018）。GAS,MTL,脾胃培元方治疗后PGE2表达明显升高(P<.001)。脾胃培元方治疗CAG疗效确切,安全性高。
